论文部分内容阅读
目的观察乙肝-肝硬化联合应用恩替卡韦与复方鳖甲软肝片的疗效。方法利用随机单盲法,将我院近期接收的乙肝-肝硬化者84例分成试验组与对照组,每组42例。试验组联合应用恩替卡韦和复方鳖甲软肝片,对照组仅接受恩替卡韦治疗。观察两组疗效,比较肝功能以及肝纤维化指标的改善程度。结果两组用药后肝功能均得到改善,试验组的改善程度明显优于对照组,差异具有统计学意义(P<0.05);针对用药后的血清肝纤维化指标水平,试验组明显低于对照组,差异具有统计学意义(P<0.05)。结论将恩替卡韦、复方鳖甲软肝片联合用于乙肝-肝硬化中,有助于肝功能的恢复,具临床应用价值。
Objective To observe the curative effect of entecavir and Fufang Biejia Ruangan Tablet combined with hepatitis B-cirrhosis. Methods Using randomized single-blind method, 84 cases of hepatitis B-cirrhosis received in our hospital were divided into experimental group and control group with 42 cases in each group. The experimental group was treated with entecavir and Fufang Biejia Ruangan tablets, while the control group received entecavir alone. The curative effect of two groups were observed, and the improvement of liver function and liver fibrosis index were compared. Results The liver function of the two groups were improved, the improvement of the experimental group was significantly better than the control group, the difference was statistically significant (P <0.05); for the treatment of serum liver fibrosis indicators, the experimental group was significantly lower than the control group Group, the difference was statistically significant (P <0.05). Conclusion Combination of entecavir and Fufang Biejia Ruangan Pian in hepatitis B-cirrhosis contributes to the recovery of liver function and has clinical value.